Skip to main content

Advertisement

Table 1 Clinical pathway descriptors in Cochrane reviews (n = 33)

From: Defining the clinical pathway in cochrane diagnostic test accuracy reviews

Clinical Pathway Descriptors Ever reported in any section (%)
1 Target condition  
1.1 Is the target condition defined? 33 (100)
1.2 Are subcategories of the target condition defined? 21 (64)
1.3 Are the following aspects defined:  
 frequency 29 (89)
 severity 26 (80)
 prognosis 24 (74)
 possible treatment 29 (89)
1.4 Is the relevance of the target condition explained in terms of downstream consequences? 24 (74)
2 Index test  
2.1 Is the purpose of the index test defined? 33 (100)
2.2 Is the role of the index test defined? 19 (57)
2.3 Are test variations included? 15 (46)
2.4 Are test specifications defined? 16 (49)
3 Clinical pathway  
3.1 Is the existing pathway of patients defined as:  
 how patients might present? 23 (69)
 the point in the pathway where the index test might be considered 26 (80)
3.2 Are prior tests identified according to:  
 clinical history and examination 27 (83)
 healthcare setting 22 (66)
3.3 Is the patient or population receiving the index test identified according to:  
 Clinical Pathway Descriptors Ever reported in any section (%)
 stage or disease severity 16 (49)
 age 12 (37)
 gender 12 (37)
 has the patient received single or multiple assessments prior to index testing 21 (63)
3.4 Are alternative tests described 27 (83)
3.5 Is it explicit how the index test/strategy compares to the existing test/strategy? Items to consider are:  
 are existing tests described 20 (60)
 is it clear if the existing test is current practice and/or reference standard 19 (57)
3.6 Is the impact of the index test on downstream clinical management action(s) explicit? 17 (51)
3.7 Is it explicit how index test/strategy when compared to current practice affects downstream outcomes? 17 (51)
3.8 Are the downstream consequences differentially described according to the 4 test accuracy categories (TP, TN,FP, FN) as follows:  
 TP : is there effective treatment or further testing needed? 14 (43)
 TN: re-testing, FU and/or intervals 9 (26)
 FP: consequences to this group 9 (26)
 FN: consequences to this group 8 (23)
  1. Normal font refer to existing Cochrane criteria in the Cochrane DTA Handbooks; italics refer to additional descriptors included by us